FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2097930057> ?p ?o ?g. }

• W2097930057 endingPage "396" @default.
• W2097930057 startingPage "386" @default.
• W2097930057 abstract "Whether androgen deprivation therapy (ADT) for men with prostate cancer (PCa) increases the risk of cardiovascular disease (CVD) remains controversial. Pooled analyses using data from randomised controlled trials suggest no increased risk of fatal CVD following ADT, but no pooled analyses exist for observational studies.To perform a meta-analysis using observational data on ADT and risk of CVD events in men with PCa.PubMed and Embase were searched using predefined inclusion criteria to perform meta-analyses on associations between types of ADT and nonfatal and fatal CVD outcomes using information from observational studies. Random effects meta-analyses were conducted to estimate relative risks (RRs) and 95% confidence intervals (CIs).A total of eight observational studies were identified studying at least one type of ADT and a nonfatal or fatal CVD outcome. The RR for risk of any type of nonfatal CVD was 1.38 (95% CI, 1.29-1.48) for men with PCa on gonadotropin-releasing hormone (GnRH) agonists, compared with men not treated with ADT. When analysing nonfatal ischemic heart disease only, the RR was 1.39 (95% CI, 1.26-1.54). The associations between GnRH agonists and nonfatal or fatal myocardial infarction or stroke were even stronger: RR: 1.57 (95% CI, 1.26-1.94) and RR: 1.51 (95% CI, 1.24-1.84), respectively. The results for other types of ADT in relation to the risk of any nonfatal CVD were RR: 1.44 (95% CI, 1.28-1.62) for orchiectomy and RR: 1.21 (95% CI, 1.07-1.367) for antiandrogens.Observational data show a consistent positive association between ADT and the risk of CVD. This finding supports the need for future randomised trials of PCa patients that include older patients and men with multiple comorbidities to better reflect the general population.We investigated all the available data from observational studies on hormonal treatment for prostate cancer and its possible cardiovascular adverse effects. We found consistent evidence that this treatment may increase the risk of cardiovascular disease." @default.
• W2097930057 created "2016-06-24" @default.
• W2097930057 creator A5003951535 @default.
• W2097930057 creator A5008076499 @default.
• W2097930057 creator A5033731052 @default.
• W2097930057 creator A5037006190 @default.
• W2097930057 creator A5061615952 @default.
• W2097930057 creator A5066655122 @default.
• W2097930057 date "2015-09-01" @default.
• W2097930057 modified "2023-10-16" @default.
• W2097930057 title "Quantifying Observational Evidence for Risk of Fatal and Nonfatal Cardiovascular Disease Following Androgen Deprivation Therapy for Prostate Cancer: A Meta-analysis" @default.
• W2097930057 cites W1510648320 @default.
• W2097930057 cites W1566635326 @default.
• W2097930057 cites W1659741523 @default.
• W2097930057 cites W1909369860 @default.
• W2097930057 cites W1918938119 @default.
• W2097930057 cites W1964172790 @default.
• W2097930057 cites W1966947676 @default.
• W2097930057 cites W1971613113 @default.
• W2097930057 cites W2004509655 @default.
• W2097930057 cites W2006286039 @default.
• W2097930057 cites W2010024475 @default.
• W2097930057 cites W2011581813 @default.
• W2097930057 cites W2014799253 @default.
• W2097930057 cites W2030172654 @default.
• W2097930057 cites W2034254687 @default.
• W2097930057 cites W2041153367 @default.
• W2097930057 cites W2049473916 @default.
• W2097930057 cites W2062571534 @default.
• W2097930057 cites W2068205696 @default.
• W2097930057 cites W2073426012 @default.
• W2097930057 cites W2074061641 @default.
• W2097930057 cites W2081052928 @default.
• W2097930057 cites W2082540132 @default.
• W2097930057 cites W2085087376 @default.
• W2097930057 cites W2087107662 @default.
• W2097930057 cites W2089907071 @default.
• W2097930057 cites W2090327260 @default.
• W2097930057 cites W2090557388 @default.
• W2097930057 cites W2098998490 @default.
• W2097930057 cites W2099037568 @default.
• W2097930057 cites W2105310697 @default.
• W2097930057 cites W2109315184 @default.
• W2097930057 cites W2111561627 @default.
• W2097930057 cites W2112874251 @default.
• W2097930057 cites W2113791652 @default.
• W2097930057 cites W2115201106 @default.
• W2097930057 cites W2119283349 @default.
• W2097930057 cites W2122952982 @default.
• W2097930057 cites W2123230901 @default.
• W2097930057 cites W2127345848 @default.
• W2097930057 cites W2138170248 @default.
• W2097930057 cites W2140905531 @default.
• W2097930057 cites W2142359566 @default.
• W2097930057 cites W2144498681 @default.
• W2097930057 cites W2148539277 @default.
• W2097930057 cites W2158827225 @default.
• W2097930057 cites W2165990809 @default.
• W2097930057 cites W2168718800 @default.
• W2097930057 cites W2616141209 @default.
• W2097930057 cites W2732251850 @default.
• W2097930057 cites W64014791 @default.
• W2097930057 doi "https://doi.org/10.1016/j.eururo.2014.11.039" @default.
• W2097930057 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25484142" @default.
• W2097930057 hasPublicationYear "2015" @default.
• W2097930057 type Work @default.
• W2097930057 sameAs 2097930057 @default.
• W2097930057 citedByCount "205" @default.
• W2097930057 countsByYear W20979300572015 @default.
• W2097930057 countsByYear W20979300572016 @default.
• W2097930057 countsByYear W20979300572017 @default.
• W2097930057 countsByYear W20979300572018 @default.
• W2097930057 countsByYear W20979300572019 @default.
• W2097930057 countsByYear W20979300572020 @default.
• W2097930057 countsByYear W20979300572021 @default.
• W2097930057 countsByYear W20979300572022 @default.
• W2097930057 countsByYear W20979300572023 @default.
• W2097930057 crossrefType "journal-article" @default.
• W2097930057 hasAuthorship W2097930057A5003951535 @default.
• W2097930057 hasAuthorship W2097930057A5008076499 @default.
• W2097930057 hasAuthorship W2097930057A5033731052 @default.
• W2097930057 hasAuthorship W2097930057A5037006190 @default.
• W2097930057 hasAuthorship W2097930057A5061615952 @default.
• W2097930057 hasAuthorship W2097930057A5066655122 @default.
• W2097930057 hasBestOaLocation W20979300571 @default.
• W2097930057 hasConcept C121608353 @default.
• W2097930057 hasConcept C126322002 @default.
• W2097930057 hasConcept C143998085 @default.
• W2097930057 hasConcept C23131810 @default.
• W2097930057 hasConcept C2777899217 @default.
• W2097930057 hasConcept C2780192828 @default.
• W2097930057 hasConcept C44249647 @default.
• W2097930057 hasConcept C71924100 @default.
• W2097930057 hasConcept C82789193 @default.
• W2097930057 hasConcept C95190672 @default.
• W2097930057 hasConceptScore W2097930057C121608353 @default.
• W2097930057 hasConceptScore W2097930057C126322002 @default.
• W2097930057 hasConceptScore W2097930057C143998085 @default.

• next